{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:37:44Z","timestamp":1770359864823,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01933-1","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:45:51Z","timestamp":1769125551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are diagnostic technologies for alzheimer\u2019s disease and dementia cost-effective? A systematic review of economic evaluations"],"prefix":"10.1186","volume":"18","author":[{"given":"Munira","family":"Kashem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Haldenby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juwairiya Fatima","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshaan Asim","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyprian M.","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehzad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"1933_CR1","unstructured":"Dementia. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Cited 2024 Oct 15."},{"key":"1933_CR2","unstructured":"ADI -. Dementia facts & figures. Available from: https:\/\/www.alzint.org\/about\/dementia-facts-figures\/. Cited 2024 Oct 15."},{"key":"1933_CR3","unstructured":"The top 10. causes of death. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Cited 2024 Oct 15."},{"key":"1933_CR4","doi-asserted-by":"crossref","unstructured":"Chen S, Cao Z, Nandi A, Counts N, Jiao L, Prettner K et al. The global macroeconomic burden of Alzheimer\u2019s disease and other dementias: estimates and projections for 152 countries or territories. The Lancet Global Health. 2024;12(9):e1534\u201343.","DOI":"10.1016\/S2214-109X(24)00264-X"},{"key":"1933_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2023.09.008","volume":"40","author":"LX Tay","year":"2024","unstructured":"Tay LX, Ong SC, Tay LJ, Ng T, Parumasivam T. Economic burden of Alzheimer\u2019s disease: a systematic review. Value Health Reg Issues. 2024;40:1\u201312.","journal-title":"Value Health Reg Issues"},{"key":"1933_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12883-023-03353-w","volume":"23","author":"V Crowell","year":"2023","unstructured":"Crowell V, Reyes A, Zhou SQ, Vassilaki M, Gsteiger S, Gustavsson A. Disease severity and mortality in alzheimer\u2019s disease: an analysis using the U.S. National alzheimer\u2019s coordinating center uniform data set. BMC Neurol. 2023;23:302.","journal-title":"BMC Neurol"},{"issue":"1","key":"1933_CR7","doi-asserted-by":"publisher","first-page":"2337452","DOI":"10.2217\/fnl-2023-0024","volume":"19","author":"KS Frederiksen","year":"2024","unstructured":"Frederiksen KS, Arus XM, Zetterberg H, Gauthier S, Boada M, Pytel V, et al. Focusing on earlier diagnosis of alzheimer\u2019s disease. Future Neurol. 2024;19(1):2337452.","journal-title":"Future Neurol"},{"issue":"7","key":"1933_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group* under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u2013939.","journal-title":"Neurology"},{"issue":"8","key":"1933_CR9","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimer\u2019s Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1933_CR10","unstructured":"Lecanemab Approved for Treatment of Early Alzheimer\u2019s Disease. Alzheimer\u2019s Disease and Dementia. Available from: https:\/\/alz.org\/alzheimers-dementia\/treatments\/lecanemab-leqembi. Cited 2024 Oct 16."},{"key":"1933_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.trci.2019.06.001","volume":"5","author":"R Wittenberg","year":"2019","unstructured":"Wittenberg R, Knapp M, Karagiannidou M, Dickson J, Schott JM. Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer\u2019s disease patients. Alzheimers Dement (N Y). 2019;5:382\u20137.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"1933_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jalz.2013.02.005","volume":"10","author":"RLH Handels","year":"2014","unstructured":"Handels RLH, Wolfs CAG, Aalten P, Joore MA, Verhey FRJ, Severens JL. Diagnosing Alzheimer\u2019s disease: a systematic review of economic evaluations. Alzheimers Dement. 2014;10(2):225\u201337.","journal-title":"Alzheimers Dement"},{"key":"1933_CR13","unstructured":"Odnoletkova I. CHEC-Extended: A tool for the quality assessment of economic evaluations of healthcare interventions. 2014."},{"issue":"10","key":"1933_CR14","doi-asserted-by":"publisher","first-page":"e0205233","DOI":"10.1371\/journal.pone.0205233","volume":"13","author":"Cost-effectiveness of","year":"2018","unstructured":"Cost-effectiveness of. GeneXpert and LED-FM for diagnosis of pulmonary tuberculosis: A systematic review. PLoS ONE. 2018;13(10):e0205233.","journal-title":"PLoS ONE"},{"key":"1933_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcskn.2023.100008","volume":"1","author":"LCJ Van Delft","year":"2023","unstructured":"Van Delft LCJ, Kelleners-Smeets NWJ, Peeters A, Mosterd K, Essers BAB. A systematic review of economic evaluations for the interventions of superficial basal cell carcinoma. EJC Skin Cancer. 2023;1:100008.","journal-title":"EJC Skin Cancer"},{"issue":"4","key":"1933_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/03007995.2016.1277197","volume":"33","author":"J Hornberger","year":"2017","unstructured":"Hornberger J, Bae J, Watson I, Johnston J, Happich M. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer\u2019s disease \u2013 the case of Florbetapir. Curr Med Res Opin. 2017;33(4):675\u201385.","journal-title":"Curr Med Res Opin"},{"key":"1933_CR17","unstructured":"Hornberger J, Michalopoulos S, Dai M, Andrade P, Dilla T, Happich M. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective. J Ment Health Policy Econ. 2015;18(2):63\u201373."},{"issue":"2","key":"1933_CR18","first-page":"253","volume":"43","author":"DH Silverman","year":"2002","unstructured":"Silverman DH, Gambhir SS, Huang HW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med. 2002;43(2):253\u201366.","journal-title":"J Nucl Med."},{"issue":"1","key":"1933_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00406-022-01439-z","volume":"273","author":"J Contador","year":"2023","unstructured":"Contador J, Vargas-Mart\u00ednez AM, S\u00e1nchez-Valle R, Trapero-Bertran M, Llad\u00f3 A. Cost-effectiveness of Alzheimer\u2019s disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis. Eur Arch Psychiatry Clin Neurosci. 2023;273(1):243\u201352.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"1933_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1148\/radiol.2282020915","volume":"228","author":"PM McMahon","year":"2003","unstructured":"McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology. 2003;228(2):515\u201322.","journal-title":"Radiology"},{"issue":"1","key":"1933_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12962-021-00300-9","volume":"19","author":"YS Lee","year":"2021","unstructured":"Lee YS, Youn H, Jeong HG, Lee TJ, Han JW, Park JH, et al. Cost-effectiveness of using amyloid positron emission tomography in individuals with mild cognitive impairment. Cost Eff Resour Alloc. 2021;19(1):50.","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"1933_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/0272989X8500500309","volume":"5","author":"DG Simon","year":"1985","unstructured":"Simon DG, Lubin MF. Cost-effectiveness of computerized tomography and magnetic resonance imaging in dementia. Med Decis Mak. 1985;5(3):335\u201351.","journal-title":"Med Decis Mak"},{"key":"1933_CR23","doi-asserted-by":"crossref","unstructured":"Biasutti M, Dufour N, Ferroud C, Dab W, Temime L. Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer\u2019s Disease. Dowdy DW, editor. PLoS ONE. 2012;7(4):e35559.","DOI":"10.1371\/journal.pone.0035559"},{"issue":"1","key":"1933_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1148\/radiology.217.1.r00se1358","volume":"217","author":"PM McMahon","year":"2000","unstructured":"McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology. 2000;217(1):58\u201368.","journal-title":"Radiology"},{"issue":"1","key":"1933_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/ADR-180098","volume":"3","author":"FS Prato","year":"2019","unstructured":"Prato FS, Pavlosky WF, Foster SC, Thiessen JD, Beaujot RP. Screening for dementia caused by modifiable lifestyle choices using hybrid PET\/MRI. ADR. 2019;3(1):31\u201345.","journal-title":"ADR"},{"issue":"1","key":"1933_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-017-0243-0","volume":"9","author":"SAW Lee","year":"2017","unstructured":"Lee SAW, Sposato LA, Hachinski V, Cipriano LE. Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):18.","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"1933_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s41669-017-0054-z","volume":"2","author":"TL Michaud","year":"2018","unstructured":"Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM. Using cerebrospinal fluid biomarker testing to target treatment to patients with mild cognitive impairment: a cost-effectiveness analysis. Pharmacoecon Open. 2018;2(3):309\u201323.","journal-title":"Pharmacoecon Open"},{"key":"1933_CR28","doi-asserted-by":"crossref","unstructured":"Valc\u00e1rcel-Nazco C, Perestelo-P\u00e9rez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P. Cost-Effectiveness of the use of biomarkers in cerebrospinal fluid for alzheimer\u2019s disease. JAD. 2014;42(3):777\u201388.","DOI":"10.3233\/JAD-132216"},{"key":"1933_CR29","doi-asserted-by":"crossref","unstructured":"Handels RLH, Wimo A, Dodel R, Kramberger MG, Visser PJ, Molinuevo JL et al. Cost-Utility of Using Alzheimer\u2019s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. Vandepitte S, editor. JAD. 2017;60(4):1477\u201387.","DOI":"10.3233\/JAD-170324"},{"key":"1933_CR30","doi-asserted-by":"crossref","unstructured":"Handels R, Wesenhagen K, Tijms B, Teunissen C, Visser PJ, J\u00f6nsson L. Potential cost-effectiveness of individualized medicine in prodromal Alzheimer\u2019s disease by demographic, clinical and cerebrospinal fluid proteomics factors. 2023. Available from:\u00a0http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.01.24.23284478. Cited 2024 Sept 10.","DOI":"10.1101\/2023.01.24.23284478"},{"issue":"8","key":"1933_CR31","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jalz.2015.02.009","volume":"11","author":"RLH Handels","year":"2015","unstructured":"Handels RLH, Joore MA, Tran-Duy A, Wimo A, Wolfs CAG, Verhey FRJ, et al. Early cost\u2010utility analysis of general and cerebrospinal fluid\u2010specific Alzheimer\u2019s disease biomarkers for hypothetical disease\u2010modifying treatment decision in mild cognitive impairment. Alzheimers Dement. 2015;11(8):896\u2013905.","journal-title":"Alzheimers Dement"},{"key":"1933_CR32","first-page":"10","volume":"1","author":"C Udeh-Momoh","year":"2021","unstructured":"Udeh-Momoh C, Zheng B, Sandebring-Matton A, Novak G, Kivipelto M, J\u00f6nsson L, et al. Blood derived amyloid biomarkers for alzheimer\u2019s disease prevention. J Prev Alz Dis. 2021;1:10.","journal-title":"J Prev Alz Dis"},{"issue":"1","key":"1933_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3233\/JAD-141632","volume":"44","author":"SY Yu","year":"2015","unstructured":"Yu SY, Lee TJ, Jang SH, Han JW, Kim TH, Kim KW. Cost-effectiveness of nationwide opportunistic screening program for dementia in South Korea. JAD. 2015;44(1):195\u2013204.","journal-title":"JAD"},{"issue":"12","key":"1933_CR34","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/gps.4626","volume":"32","author":"T Tong","year":"2017","unstructured":"Tong T, Thokala P, McMillan B, Ghosh R, Brazier J. Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care. Int J Geriatr Psychiatry. 2017;32(12):1392\u2013400.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"1933_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/archgenpsychiatry.2008.544","volume":"66","author":"CAG Wolfs","year":"2009","unstructured":"Wolfs CAG, Dirksen CD, Kessels A, Severens JL, Verhey FRJ. Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial. Arch Gen Psychiatry. 2009;66(3):313.","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"1933_CR36","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1109\/TBME.2012.2212278","volume":"60","author":"J Escudero","year":"2013","unstructured":"Escudero J, Ifeachor E, Zajicek JP, Green C, Shearer J, Pearson S. Machine learning-based method for personalized and cost-effective detection of alzheimer\u2019s disease. IEEE Trans Biomed Eng. 2013;60(1):164\u20138.","journal-title":"IEEE Trans Biomed Eng"},{"key":"1933_CR37","doi-asserted-by":"crossref","unstructured":"Darab MG, Engel L, Henzler D, Lauerer M, Nagel E, Brown V et al. Model-Based Economic Evaluations of Interventions for Dementia: An Updated Systematic Review and Quality Assessment. Appl Health Econ Health Policy. 2024;22(4):503\u201325.","DOI":"10.1007\/s40258-024-00878-0"},{"key":"1933_CR38","doi-asserted-by":"crossref","unstructured":"Pekkala T, Hall A, Ngandu T, van Gils M, Helisalmi S, H\u00e4nninen T et al. Detecting Amyloid Positivity in Elderly With Increased Risk of Cognitive Decline. Front Aging Neurosci. 2020;12. Available from: https:\/\/www.frontiersin.org\/journals\/aging-neuroscience\/articles\/10.3389\/fnagi.2020.00228\/full. Cited 2024 Oct 22.","DOI":"10.3389\/fnagi.2020.00228"},{"issue":"2","key":"1933_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1567205011310020011","volume":"10","author":"A Sk\u00f6ldunger","year":"2013","unstructured":"Sk\u00f6ldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in alzheimer\u2019s disease\u2013a simulation study. Curr Alzheimer Res. 2013;10(2):207\u201316.","journal-title":"Curr Alzheimer Res"},{"key":"1933_CR40","doi-asserted-by":"crossref","unstructured":"O\u2019Mahony JF, Newall AT, van Rosmalen J. Dealing with time in health economic evaluation: methodological issues and recommendations for practice. PharmacoEconomics. 2015;25(12):1255.","DOI":"10.1007\/s40273-015-0309-4"},{"key":"1933_CR41","unstructured":"Alzheimers Rates by. Country 2024. Available from: https:\/\/worldpopulationreview.com\/country-rankings\/alzheimers-rates-by-country. Cited 2024 Oct 24."},{"issue":"1","key":"1933_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107134","volume":"213","author":"X Zhang","year":"2022","unstructured":"Zhang X, Lian S, Zhang Y, Zhao Q. Efficacy and safety of donepezil for mild cognitive impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2022;213(1):107134.","journal-title":"Clin Neurol Neurosurg"},{"key":"1933_CR43","doi-asserted-by":"crossref","unstructured":"Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment - Russ, TC \u2013\u20092012 | Cochrane Library. Available from: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD009132.pub2\/full. Cited 2025 Oct 7.","DOI":"10.1002\/14651858.CD009132"},{"issue":"8","key":"1933_CR44","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/jamainternmed.2023.1749","volume":"183","author":"JC Arbanas","year":"2023","unstructured":"Arbanas JC, Damberg CL, Leng M, Harawa N, Sarkisian CA, Landon BE, et al. Estimated annual spending on Lecanemab and its ancillary costs in the US medicare program. JAMA Intern Med. 2023;183(8):885\u20139.","journal-title":"JAMA Intern Med"},{"key":"1933_CR45","unstructured":"No.24\u201356. Available from: https:\/\/www.eisai.com\/news\/2024\/pdf\/enews202456.pdf.pdf. Cited 2025 Oct 9."},{"issue":"4","key":"1933_CR46","doi-asserted-by":"publisher","first-page":"928","DOI":"10.14283\/jpad.2024.67","volume":"11","author":"S Aye","year":"2024","unstructured":"Aye S, Handels R, Winblad B, J\u00f6nsson L. Optimising alzheimer\u2019s disease diagnosis and treatment: assessing cost-utility of integrating blood biomarkers in clinical practice for disease-modifying treatment. J Prev Alzheimers Dis. 2024;11(4):928\u201342.","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"1933_CR47","doi-asserted-by":"publisher","first-page":"e209218","DOI":"10.1212\/WNL.0000000000209218","volume":"102","author":"HV Nguyen","year":"2024","unstructured":"Nguyen HV, Mital S, Knopman DS, Alexander GC. Cost-effectiveness of Lecanemab for individuals with early-stage alzheimer disease. Neurology. 2024;102(7):e209218.","journal-title":"Neurology"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01933-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01933-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01933-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:38:02Z","timestamp":1770305882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01933-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1933"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01933-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}